PhaseBio touts 'breakthrough' badge for bloodthinner reversal agent licensed from AstraZeneca, shares leap

At PhaseBio, the game plan has been to hustle its Brilinta reversal agent, PB2452, down what it sees as a short path to approval, unlocking revenue that will then fund more expensive trials of its pulmonary arterial hypertension drug. With a new breakthrough therapy designation, execs are marching onward with boosted confidence.